Replimune Group (REPL) Expected to Post Quarterly Earnings on Thursday

Replimune Group (NASDAQ:REPL) will likely be releasing its Q1 2027 results before the market opens on Thursday, August 6th. Analysts expect Replimune Group to post earnings of ($0.6437) per share and revenue of $13.6010 million for the quarter. Individuals can check the company’s upcoming Q1 2027 earning results page for the latest details on the call scheduled for Thursday, August 13, 2026 at 7:00 AM ET.

Replimune Group (NASDAQ:REPL) last released its quarterly earnings data on Monday, June 29th. The company reported ($0.76) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.66) by ($0.10). On average, analysts expect Replimune Group to post $-3 EPS for the current fiscal year and $-1 EPS for the next fiscal year.

Replimune Group Price Performance

REPL stock opened at $11.92 on Wednesday. The company has a debt-to-equity ratio of 0.63, a quick ratio of 4.79 and a current ratio of 4.79. The company’s fifty day moving average price is $9.77 and its 200-day moving average price is $7.44. Replimune Group has a one year low of $1.50 and a one year high of $13.86. The company has a market capitalization of $1.00 billion, a PE ratio of -3.53 and a beta of 0.88.

Insider Buying and Selling

In related news, insider Christopher Sarchi sold 12,000 shares of Replimune Group stock in a transaction dated Monday, June 1st. The stock was sold at an average price of $9.24, for a total value of $110,880.00. Following the completion of the transaction, the insider owned 180,962 shares in the company, valued at approximately $1,672,088.88. This trade represents a 6.22% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Corporate insiders own 5.40% of the company’s stock.

Hedge Funds Weigh In On Replimune Group

Institutional investors and hedge funds have recently modified their holdings of the stock. Invesco Ltd. increased its position in shares of Replimune Group by 297.3% during the 4th quarter. Invesco Ltd. now owns 613,015 shares of the company’s stock valued at $5,959,000 after purchasing an additional 458,714 shares during the last quarter. XTX Topco Ltd bought a new stake in Replimune Group in the fourth quarter worth $322,000. Virtus Investment Advisers LLC lifted its position in Replimune Group by 127.0% in the fourth quarter. Virtus Investment Advisers LLC now owns 26,133 shares of the company’s stock worth $254,000 after buying an additional 14,622 shares during the last quarter. SummitTX Capital L.P. purchased a new position in Replimune Group during the fourth quarter worth $1,058,000. Finally, Susquehanna Portfolio Strategies LLC purchased a new position in Replimune Group during the fourth quarter worth $650,000. Hedge funds and other institutional investors own 92.53% of the company’s stock.

Wall Street Analyst Weigh In

REPL has been the topic of several research analyst reports. Jefferies Financial Group reiterated a “hold” rating and issued a $2.00 price target (down from $13.00) on shares of Replimune Group in a research note on Monday, April 13th. Weiss Ratings upgraded Replimune Group from a “sell (e+)” rating to a “sell (d-)” rating in a research report on Monday, July 20th. Wall Street Zen raised Replimune Group from a “strong sell” rating to a “sell” rating in a report on Saturday, May 23rd. Wolfe Research upgraded Replimune Group to an “outperform” rating in a research report on Tuesday. Finally, Leerink Partners raised Replimune Group from a “market perform” rating to an “outperform” rating and increased their price target for the company from $11.00 to $17.00 in a research note on Tuesday. One investment analyst has rated the stock with a Strong Buy rating, five have assigned a Buy rating, two have assigned a Hold rating and two have given a Sell rating to the stock. According to data from MarketBeat, Replimune Group currently has an average rating of “Moderate Buy” and a consensus target price of $11.43.

Replimune Group Company Profile

Replimune Group, Inc is a clinical‐stage biotechnology company focused on developing next‐generation oncolytic immunotherapies for the treatment of solid tumors. The company’s proprietary “RP” platform leverages genetically engineered herpes simplex virus type 1 (HSV-1) vectors armed with immunomodulatory payloads to selectively infect, replicate within and destroy cancer cells, while also stimulating systemic antitumor immune responses.

Replimune’s lead candidate, RP1, incorporates GM-CSF and a fusogenic protein to enhance both direct oncolysis and immune activation.